Butyrolactone: more than a kinase inhibitor?
Bloom
Joanna
J
Department of Pathology and NYU Cancer Center; MSB599, New York University School of Medicine; 550 First Avenue; New York, New York 10016, USA.
Pagano
Michele
M
D000818:Animals; D002090:Butyrophenones / Q000494:pharmacology*; D016203:CDC2 Protein Kinase / Q000037:antagonists & inhibitors; D042846:CDC2-CDC28 Kinases; D002453:Cell Cycle; D051357:Cyclin-Dependent Kinase 2; D050759:Cyclin-Dependent Kinase Inhibitor p21; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors*; D016213:Cyclins / Q000378:metabolism*; D004249:DNA Damage; D010453:Peptide Synthases / Q000378:metabolism; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D044843:SKP Cullin F-Box Protein Ligases; D015398:Signal Transduction; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
D002090:Butyrophenones; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D016159:Tumor Suppressor Protein p53; D044843:SKP Cullin F-Box Protein Ligases; D017346:Protein Serine-Threonine Kinases; D016203:CDC2 Protein Kinase; D042846:CDC2-CDC28 Kinases; D051357:Cyclin-Dependent Kinase 2; D018844:Cyclin-Dependent Kinases; D010453:Peptide Synthases